Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2006

View Archived Issues

IND filing for XL-281

R-1626 begins phase II trials in chronic hepatitis C

Agreement for humanization of BioArctic's antibody for Alzheimer's disease

Phoqus to advance Chronocort into phase II trials for adrenal insufficiency

Delay to gaboxadol NDA filing

G-4460 studied in phase I trial in advanced cancer

End-of-phase II meeting for NRP-290

Taiho follows committee's advice on gastric cancer study of TS-1

Improved outcomes with Surfaxin in bronchopulmonary dysplasia

Polidocasklerol for varicose veins set for December launch in Japan

Novo Nordisk withdraws E.U. application to expand repaglinide product labels

Neurochem submits complete response to Kiacta approvable letter

BVT-28949 begins phase II study for glaucoma

Tezampanel begins phase IIb for treatment of acute migraine

AD-337 studied in fibromyalgia syndrome proof-of-principle study

Ad5-TRAIL gene therapy studied in phase I for prostate cancer

XEN-D0101 begins phase I development for atrial fibrillation

New data presented at EADV on agents under development at Barrier Therapeutics

Retapamulin effective in treating impetigo

Preclinical studies detail CNS-7056X characteristics

New therapeutics for cancer covered in recent patent literature

Novel agents for thrombotic disorders reported in recent Pfizer and Fournier patents

New peptides for treating wrinkles reported by Rohto

Novel choline analogue enhances cognition in monkeys

Targeting sEH as a novel strategy for inflammatory pain relief

SP-04 and its metabolite: a novel therapeutic approach for Alzheimer's disease

Spotlight on novel macrolide derivatives developed at Enanta

FDA accepts NDA for zileuton CR

Januvia approved for type 2 diabetes

NovoSeven approved for acquired hemophilia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...